MSCE

CHOP and Penn Launch Kidney Innovation Center to Accelerate Discovery and Improve Treatment of Kidney Disease Across the Lifespan

Retrieved on: 
Friday, August 26, 2022
National, Research, Hospital of the University of Pennsylvania, University, Penn, News, Medical school, Culture, Epidemiology, Pathology, Home, Biomedical Research, NIH, Kidney disease, MSCE, Pediatrics, Biostatistics, Prussia, Adult, Patient, Health, Workforce, Genetics, Death, University of Pennsylvania Health System, Raymond, School, Pharmacology, Hospital, Biochemistry, Psychology, Computational biology, Division, Children's Hospital of Philadelphia, Disease, Perelman School of Medicine at the University of Pennsylvania, MD, Genomics, CHOP, Physiology, Honors student, Doctor of Philosophy, Academic health science centre, U.S. News & World Report Best Hospitals Rankings, Education, Philadelphia, Veterinary medicine, Pharmaceutical industry, Nephrology, Pennsylvania Hospital

PHILADELPHIA, Aug. 26, 2022 /PRNewswire/ -- In an effort to improve the lives of children and adults with kidney disease, Children's Hospital of Philadelphia (CHOP) and Penn Medicine are jointly launching the Penn-CHOP Kidney Innovation Center. The first-of-its-kind center will advance research to transform patient care for those of all ages, focusing on the early detection, prevention, and treatment of kidney disease and its complications.

Key Points: 
  • PHILADELPHIA, Aug. 26, 2022 /PRNewswire/ -- In an effort to improve the lives of children and adults with kidney disease, Children's Hospital of Philadelphia (CHOP) and Penn Medicine are jointly launching the Penn-CHOP Kidney Innovation Center .
  • The first-of-its-kind center will advance research to transform patient care for those of all ages, focusing on the early detection, prevention, and treatment of kidney disease and its complications.
  • "This center will draw from experts across both institutions, using interdisciplinary collaboration as the driving force to accelerate research that improves the health and well-being of all patients with kidney disease."
  • The Kidney Innovation Center brings together scientists in clinical epidemiology, biostatistics, bioinformatics, computational biology, genetics, pathology, physiology, biochemistry, immunology, genomics, pharmacology, psychology, and education.

MedMatch Network Names Joseph L. Ortiz Chief Innovation and Operations Officer

Retrieved on: 
Tuesday, August 2, 2022
Amos, Time, Digital technology, Company, PMP, Entrepreneurship, IP, Strategic management, NCR, Growth, Marketing, Summit Medical Group, ITIL, MBA, MSCE, Patient, Engineering, Motorola, FACS, Medical device, Health insurance, MD

BOCA RATON, Fla., Aug. 2, 2022 /PRNewswire-PRWeb/ -- MedMatch Network, an innovative healthcare information technology firm focused on facilitating patient referral management and information exchange for seamless continuity of care, appoints Joseph L. Ortiz, MSCE, MBA, PMP, ITIL 4.0 as Chief Innovation and Operations Officer for the company. The company is poised to grow aggressively nationwide with its cloud-based platform of medical providers facilitating reliable, automated patient referral management and secure information exchange.

Key Points: 
  • Will Drive Growth, Business Strategy and Operations Execution, and the Firm's Digital Technology Competitive Advantage and IP
    BOCA RATON, Fla., Aug. 2, 2022 /PRNewswire-PRWeb/ -- MedMatch Network , an innovative healthcare information technology firm focused on facilitating patient referral management and information exchange for seamless continuity of care, appoints Joseph L. Ortiz, MSCE, MBA, PMP, ITIL 4.0 as Chief Innovation and Operations Officer for the company.
  • "Joe comes to MedMatch Network with extensive expertise and experience in the healthcare industry across healthcare technology, digital systems, software IP and entrepreneurship, and clinical practice IT and operations," said MedMatch Founder and CEO Amos Dar, MD, FACS.
  • Ortiz brings over 30 years of digital technology business experience to his role at MedMatch Network.
  • MedMatch Network provides interoperability, connecting all providers on the same platform to improve the patient journey through the healthcare system.

New Report: Nation's Chronic Lack of Investment in Public Health Puts Americans' Lives and Livelihoods at Risk

Retrieved on: 
Thursday, July 28, 2022
Death, Congress, Conditional sentence, Investment, View, Education, Poverty, De Beaumont Foundation, Gaps, CEO, SAARC COVID-19 Emergency Fund, Data, Workforce, Climate change, Risk, Emergency, COVID-19, Public health, Health promotion, Multimedia, Hospital, Assistant, Organization, Public Health Emergency Preparedness, Office of Inspector General, U.S. Department of Health and Human Services, Policy, Suicide, Disease, Disability, MSCE, Transport, Magnetic resonance, Immunization, Color, Federation, Annual report, CDC, Impact, Public health emergency, Trust for America's Health, Obesity, Health equity, Health insurance, Renewable energy, Pharmaceutical industry, Healthcare, Audit, Trust, Health

WASHINGTON, July 28, 2022 /PRNewswire/ -- Chronic underfunding has created a public health system that cannot address the nation's health security needs, its persistent health inequities, as well as emerging threats, and, was a contributing factor in the inadequate response to the COVID-19 pandemic, according to a report, The Impact of Chronic Underfunding on America's Public Health System: Trends, Risks, and Recommendations, 2022, released today by Trust for America's Health.

Key Points: 
  • TFAH is one of numerous organizations within the public health community calling for an annual $4.5 billion investment in public health infrastructure at the state, local, tribal, and territorial levels.
  • "As we navigate the next stages of the pandemic and beyond, it is critical that we modernize public health data infrastructure, grow, and diversify the public health workforce, invest in health promotion and prevention programs, and reduce health inequities.
  • Most of it could not be used to address longstanding deficits in the public health system, including ensuring the provision of basic public health services, replacing antiquated data systems, and growing the public health workforce.
  • To be adequately prepared for the next public health emergency, the nation needs to sustain higher levels of public health funding and provide more flexible funding.

Nurix Therapeutics Reports Fiscal Second Quarter 2022 Financial Results and Provides a Corporate Update

Retrieved on: 
Thursday, July 7, 2022
American Society of Clinical Oncology, Patient, Research, American Academy, GLOBE, COVID-19, Cancer, Collaboration, EHA, IND, Calendar, Clinical Ovarian Cancer & Other Gynecologic Malignancies, ASCO, Gilead, European Hematology Association, Therapy, FDA, Â, PD, AACR, SAN, Drug resistance, Investment, SEC, Cervical cancer, Intention, Forward-looking statement, Translation, Protein, MSCE, Goal, Degenerative disease, CLL, Private Securities Litigation Reform Act, Nasdaq, Memorial Sloan Kettering Cancer Center, Drug discovery, Science, Chronic lymphocytic leukemia, Enzyme, Endometrial cancer, Lymphoma, BTK, United Kingdom, Clinical trial, Lymphoid leukemia, Safety, Society, Program, Ovarian cancer, Pharmaceutical industry, Fine chemical, Vaccine, Sanofi

An archived webcast of the event can be accessed via the Events and Presentations page of the Investor section of the Nurix website.

Key Points: 
  • An archived webcast of the event can be accessed via the Events and Presentations page of the Investor section of the Nurix website.
  • Nurix anticipates presenting additional clinical results from the Phase 1a portion of the trial in the second half of 2022.
  • Nurix anticipates providing a clinical update from the run-in portion of the DeTIL-0255 Phase 1 study in the second half of 2022.
  • In the three months ended May 31, 2022, Nurix achieved a research milestone under its collaboration with Gilead and anticipates a payment of $1.5million in the third fiscal quarter of 2022.

LRA Announces Inaugural Awards Promoting Diversity in Lupus Research

Retrieved on: 
Friday, June 10, 2022
Woman, Degenerative disease, Infection, Diversity, Cognition, Board of directors, Research, Urine, Hospital for Sick Children (Toronto), HSS, Biomedical Research, Doctor of Philosophy, Lupus nephritis, SLE, Hospital for Special Surgery, Monocyte, Career development, Inflammation, Vasculitis, Blood, Brigham and Women's Hospital, Native, Multimedia, University, University of Florida, Adolescence, Brain, PRKG1, Patient, Risk, LRA, Immune system, National Bioscience Award for Career Development, Magnetic resonance imaging, Autoimmune disease, MSCE, Prevalence, Board, Heart, Hospital, Skin, CXCL13, Joint, Medical device, Medicine, Vaccine, Pharmaceutical industry, MSCI, Lupus, MD

NEW YORK, June 10, 2022 /PRNewswire/ -- The Lupus Research Alliance (LRA), the world's leading private funder of lupus research, today announced inaugural recipients of Career Development and Postdoctoral Awards to Promote Diversity in Lupus Research.

Key Points: 
  • NEW YORK, June 10, 2022 /PRNewswire/ -- The Lupus Research Alliance (LRA), the world's leading private funder of lupus research, today announced inaugural recipients of Career Development and Postdoctoral Awards to Promote Diversity in Lupus Research.
  • The Diversity in Lupus Research Award funding mechanisms aim to address underrepresentation of minorities in the scientific research profession.
  • Teodora Staeva, PhD, LRA Chief Scientific Officer said, "We congratulate the inaugural recipients of our Diversity in Lupus Research Awards and look forward to seeing how their research findings advance our understanding of lupus and result in the development of new treatment options for lupus patients.
  • Because the Lupus Research Alliance's Board of Directors funds all administrative and fundraising costs, 100% of all donations goes to support lupus research programs.

5 For The Fight Announces New Class of Cancer Research Fellows

Retrieved on: 
Thursday, June 2, 2022
Science, Other Philanthropy, Research, Oncology, Health, Philanthropy, Fund Raising, Foundation, Woman, Science, Epidemiology, Lymphatic system, Immunotherapy, Augustus A. Bird, Program, Research, Man, Neoplasm, Doctor of Philosophy, Utah Jazz, Nanomedicine, Biophysics, Melanoma, Dude, NBA, Fred Hutchinson Cancer Research Center, University of Utah, Pathology, Disease, Cancer, MA, University, Fight Cancer, Oncology nursing, Method, Melissa Reeves, Patient, Northwestern University, Qualtrics, Webster University, Genetic testing, University of California, San Francisco, Bladder cancer, San Francisco, Gynaecology, Immune system, Chromosome, MSCE, Communication, Lung cancer, Huntsman Cancer Institute, Obstetrics, Kidney cancer, Cell biology, Internal medicine, Leukemia, Biochemistry, Massachusetts Institute of Technology School of Science, Autoimmunity, Pharmaceutical industry, Medicine, Combat, MD

Their important work along with the work of other fellows in the program bring us one step closer to our goal to eradicate cancer.

Key Points: 
  • Their important work along with the work of other fellows in the program bring us one step closer to our goal to eradicate cancer.
  • This is the third class of 5 For The Fight Cancer Research Fellows, which now totals over 30 researchers.
  • To date, 5 For The Fight has raised nearly $30 million to help eradicate cancer with 100% of those funds donated directly to the worlds leading cancer researchers.
  • Heterogeneous tumors respond poorly to immunotherapy, and are common across many tumor types, including melanoma, lung cancer, bladder cancer, and kidney cancer.

Nurix Therapeutics Announces Positive Dose Finding Data in Chronic Lymphocytic Leukemia and Advances NX-2127 to Next Phase of Clinical Development

Retrieved on: 
Thursday, May 26, 2022
Lymphoma, Cancer, Program, Risk, Memorial Sloan Kettering Cancer Center, BTK, Follicular lymphoma, MTD, Lymphoid leukemia, R, Private Securities Litigation Reform Act, Survival, Enzyme, Nasdaq, Chronic lymphocytic leukemia, Patient, Waldenström's macroglobulinemia, Goal, ClinicalTrials.gov, Therapy, Lymphocytosis, Pharmacokinetics, Clinical trial, Investor, COVID-19, Adult, SAN, Intention, DLBCL, B-cell lymphoma, Index (publishing), Forward-looking statement, CLL, Safety, MSCE, SLL, Protein, MCL, SEC, Mantle cell lymphoma, GLOBE, Factor X, Pharmaceutical industry, Vaccine

The first expansion cohorts will focus on patients with chronic lymphocytic leukemia (CLL).

Key Points: 
  • The first expansion cohorts will focus on patients with chronic lymphocytic leukemia (CLL).
  • Brown, M.D., executive vice president of clinical development at Nurix.
  • The Phase 1b expansion cohorts will include up to 40 CLL patients enrolled across multiple clinical sites in the United States.
  • The Phase 1a dose escalation portion of the trial will continue to enroll non-CLL patients at doses ranging from 50mg to 300mg orally once daily.

U.S. Experienced Highest Ever Combined Rates of Deaths Due to Alcohol, Drugs, and Suicide During the COVID-19 Pandemic

Retrieved on: 
Tuesday, May 24, 2022
Well, Addiction, Well-being, Drug, Naloxone, Risk, CEO, Grief, Death, Suicide, Population, Bell Trade Act, Drug overdose, Health, Multimedia, View, Government, Nation, Degenerative disease, Pain, COVID-19, Color, American Indians, Student, Anxiety, Heart, United States Public Health Service, Combat, Trust, MSCE, School, CDC, Mental health, Center, Trust for America's Health, Korea Disease Control and Prevention Agency, District, Pharmaceutical industry, Life insurance, Medicine, Toy

WASHINGTON, May 24, 2022 /PRNewswire/ -- Deaths associated with alcohol, drugs, and suicide took the lives of 186,763 Americans in 2020, a 20 percent one year increase in the combined death rate and the highest number of substance misuse deaths ever recorded for a single year, according to a report released today by Trust for America's Health (TFAH) and Well Being Trust. In addition, provisional data from the Centers for Disease Control and Prevention show drug overdose deaths continued to increase in 2021.

Key Points: 
  • In addition, provisional data from the Centers for Disease Control and Prevention show drug overdose deaths continued to increase in 2021.
  • Increases were particularly high among young adults, American Indians/Alaska Native and Asian communities, and for those living in the Midwest.
  • The decline occurred among white people but suicide deaths for the year increased among American Indian, Black, and Latino people.
  • Suicide rates for adults ages 35-74, declined, but rates for youth and young adults increased.

Nurix Therapeutics to Host R&D Day on May 26, 2022

Retrieved on: 
Monday, May 9, 2022
CLL, Nasdaq, GLOBE, MSCE, Memorial Sloan Kettering Cancer Center, Cancer, Enzyme, Chronic lymphocytic leukemia, R, Investor, Program, Protein, SAN, Therapy, Fine chemical

SAN FRANCISCO, May 09, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs, todayannouncedit will host a research & development (R&D) day for analysts and investors that will be held on Thursday, May 26, 2022 from 8:00 a.m. to 11:00 a.m.

Key Points: 
  • SAN FRANCISCO, May 09, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs, todayannouncedit will host a research & development (R&D) day for analysts and investors that will be held on Thursday, May 26, 2022 from 8:00 a.m. to 11:00 a.m.
  • The event will include presentations from Nurixs management team, who will provide a comprehensive update on Nurixs four clinical programs, DELigase discovery platform and future development plans.
  • A live webcast, as well as a replay, will be available in the Investors section of the Nurix website under Events and Presentations .
  • Nurix is headquartered in San Francisco, California.

Neuraly Announces Completion of Enrollment in Phase 2 Clinical Trial of NLY01 in Patients with Parkinson’s Disease

Retrieved on: 
Tuesday, April 19, 2022
Science, Cardiology, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Patient, BBB, Neurology, Unified Parkinson's disease rating scale, Multiple sclerosis, Retina, Neuroprotection, Glucagon-like peptide-1 receptor, Half-life, Traffic barrier, Microglia, Brain, Â, MSCE, Review, Injection, Glaucoma, Disease, Neurodegeneration, AD, Movement disorders, Safety, Mouse, University, Neuroinflammation, D, Pharmaceutical industry, Vaccine, Bradina neuralis, PD

Neuraly, a clinical stage biotechnology company pioneering disease-modifying agents for neurodegenerative disorders, today announced the completion of patient enrollment in its Phase 2 study of NLY01 for Parkinsons disease (PD).

Key Points: 
  • Neuraly, a clinical stage biotechnology company pioneering disease-modifying agents for neurodegenerative disorders, today announced the completion of patient enrollment in its Phase 2 study of NLY01 for Parkinsons disease (PD).
  • The Phase 2 study has enrolled 255 patients across 60 clinical sites in the United States and Canada.
  • The randomized, double-blind, placebo-controlled trial is designed to assess the safety, tolerability, and efficacy of NLY01 in subjects with early PD.
  • Treatment with NLY01 slowed disease progression, improved motor and cognitive functions and extended the lifespan in mice with Parkinsons disease.